76-Year-Old Woman With a Bluish-Purple Lump in her Left Upper Medial Leg

Publication
Article
OncologyONCOLOGY Vol 34 Issue 5
Volume 34
Issue 5

Test your diagnostic knowledge with this month's Image IQ.

Copur is a medical oncologist/ hematologist at Morrison Cancer Center, Mary Lanning Healthcare in Hastings, Nebraska, and is a professor at the University of Nebraska Medical Center in Omaha, Nebraska. He is also editor-at-Large and a Community Oncology Advisory Board member at ONCOLOGY.

Wedel is a staff pathologist at Mary Lanning Healthcare.

 

Presentation

A woman, aged 76 years, presented with a bluish-purple lump in her mid- to upper medial left thigh. It started initially as a flat rash, and over a 2-month period, it turned into a mass measuring 2.5 cm by 3.1 cm (Figure 1). Work-up, including a PET-CT scan, showed the soft tissue mass on the inner thigh to have a Standardized Uptake Value of 4 (Figure 2); there were no other sites of disease. A biopsy of the lesion was performed (Figure 3).

 

 

What’s your diagnosis? 

A. Kaposi sarcoma

B. Malignant melanoma 

C. Adult soft tissue sarcoma 

D. Angiosarcoma

E. Lymphoma

 

 

CORRECT ANSWER

E. Lymphoma

 

 

Comment

Primary cutaneous diffuse large B-cell lymphoma (LBCL), leg type, is a primary cutaneous LBCL of intermediate behavior. It represents 1% to 4% of all cutaneous lymphomas and approximately 10% to 20% of all primary cutaneous LBCLs.1,2 The disease predominantly affects elderly patients, with the male-to-female ratio ranging from 1:2 to 1:4. Typically, patients present with rapidly growing, solitary or clustered, red or bluish-red nodules or tumors located on 1 or both legs, which can ulcerate.3 These lymphomas are mostly limited to the skin at presentation. Histologically, observed is either a dense, diffuse infiltrate of a monotonous population; or confluent sheets of medium to large B cells with round nuclei, prominent nucleoli, and coarse chromatin resembling centroblasts and/or immunoblasts within the dermis and subcutis. The neoplastic B cells usually express B-cell markers (CD19, CD20, CD22, CD79a). Additionally, Bcl-2, MUM1/IRF4, IgM, and FOXP1 proteins are strongly positive.4 The frequent relapses require appropriate treatment decisions and a strict follow-up of the patients. 

 

References:

1. Sokol L, Naghashpour M, Glass LF. Primary cutaneous B-cell lymphomas: recent advances in diagnosis and management. Cancer Control. 2012;19(3):236-244. doi:10.1177/107327481201900308

2. Thomas V, Dobson R, Mennel R. Primary cutaneous large B-cell lymphoma, leg type. Proc (Bayl Univ Med Cent). 2011;24(4):350-353. doi:10.1080/08998289.2011.11928757

3. Kempf W, Denisjuk N, Kerl K, et al. Primary cutaneous B-cell lymphomas. J Dtsch Dermatol Ges. 2012;10(1):12-22; quiz 23. doi:10.1111/j.1610-0387.2011.07852.x

4. Hristov AC. Primary cutaneous diffuse large B-cell lymphoma, leg type: diagnostic considerations. Arch Pathol Lab Med. 2012;136(8):876–881. doi:10.5858/arpa.2012-0195-RA

Recent Videos
Cytokine release syndrome was primarily low or intermediate in severity, with no grade 5 instances reported among those with diffuse large B-cell lymphoma.
Safety results from a phase 2 trial show that most toxicities with durvalumab treatment were manageable and low or intermediate in severity.
Investigators are currently evaluating mosunetuzumab in relapsed disease or comparing it with rituximab in treatment-naïve follicular lymphoma.
Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Harmonizing protocols across the health care system may bolster the feasibility of giving bispecifics to those with lymphoma in a community setting.
Establishment of an AYA Lymphoma Consortium has facilitated a process to better understand and address gaps in knowledge for this patient group.
Adult and pediatric oncology collaboration in assessing nivolumab in advanced Hodgkin lymphoma facilitated the phase 3 SWOG S1826 findings.
Treatment paradigms differ between adult and pediatric oncologists when treating young adults with lymphoma.
No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.
Related Content